Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.

PURPOSE We wanted to evaluate feasibility and safety of dendritic cell-based immunotherapy in patients with metastatic renal cell carcinoma (RCC). EXPERIMENTAL DESIGN Patients with metastatic RCC (n = 35) received vaccinations (i.v. or i.d.) of CD83+ autologous monocyte-derived dendritic cells (moDCs). MoDCs were loaded with lysate of cultured autologous or allogeneic permanent tumor cells (A-498) as well as keyhole limpet hemocyanin as control and helper antigen. Maturation of moDCs was induced by a combination of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, and prostaglandin E2. RESULTS Treatment was associated with transient flu-like symptoms. In 2 of 27 evaluable patients, any evidence of disease disappeared (complete response). In both cases, metastatic tissue had been the source of tumor antigen. One patient had an objective partial response. Seven patients had stable disease, the remaining 17 patients had progressive disease. In 11 of 11 patients evaluated, moDCs induced strong immune responses against keyhole limpet hemocyanin. In 5 of 6 patients tested, enhanced immune responses against oncofetal antigen (immature laminin receptor; OFA/LRP) could also be detected. The strongest responses against OFA/LRP were detectable in 2 patients with complete response and partial response, respectively. At the time of submission, mean follow up is 32 months and 8 patients are currently alive. CONCLUSIONS Our data indicate that moDC-based vaccination is well tolerated and has immunological as well as clinical effects in patients with metastatic RCC. OFA/LRP might be an attractive candidate antigen for DC-based immunotherapy of RCC.

[1]  T. Di Pucchio,et al.  Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. , 2001, Blood.

[2]  F. Marincola,et al.  Cytokines and Immune Response in the Tumor Microenvironment , 2001, Journal of immunotherapy.

[3]  S. Endres,et al.  Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. , 2001, Cancer research.

[4]  F. Tanaka,et al.  Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  G. Bartsch,et al.  Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma. , 2001, The Journal of urology.

[6]  F. Zintl,et al.  IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Lanzavecchia,et al.  Migration and Function of Antigen-Primed Nonpolarized T Lymphocytes in Vivo , 2001, The Journal of experimental medicine.

[8]  G. Bartsch,et al.  The disabled dendritic cell. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  Edgar G. Engleman,et al.  Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients1 , 2001, The Journal of Immunology.

[10]  J. Mulé,et al.  Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. , 2001, Cancer research.

[11]  M. Roncarolo,et al.  Differentiation of T Regulatory Cells by Immature Dendritic Cells , 2001, The Journal of experimental medicine.

[12]  Y. Horiguchi,et al.  Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  M. Peshwa,et al.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Jäger,et al.  The Leukotriene C4 Transporter MRP1 Regulates CCL19 (MIP-3β, ELC)–Dependent Mobilization of Dendritic Cells to Lymph Nodes , 2000, Cell.

[15]  F. Sallusto,et al.  Understanding dendritic cell and T‐lymphocyte traffic through the analysis of chemokine receptor expression , 2000, Immunological reviews.

[16]  J. Buckner,et al.  Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  T. Di Pucchio,et al.  Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice , 2000, The Journal of experimental medicine.

[18]  G. Bartsch,et al.  Mature Dendritic Cells Induce T-Helper Type-1-Dominant Immune Responses in Patients with Metastatic Renal Cell Carcinoma , 2000, Urologia Internationalis.

[19]  H. Rammensee,et al.  Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. , 1999, Blood.

[20]  J. Schlom,et al.  A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  H. Klocker,et al.  Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. , 1999, The Journal of urology.

[22]  A. Enk,et al.  Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. , 1999, Blood.

[23]  R. Coleman,et al.  Migration of human dendritic cells after injection in patients with metastatic malignancies. , 1999, Cancer research.

[24]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[25]  M. Mbizvo,et al.  Dendritic Cell-Based Immunotherapy of Renal Cell Carcinoma , 1998, Urologia Internationalis.

[26]  G. Bartsch,et al.  CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer , 1998, The Lancet.

[27]  A. Barsoum,et al.  Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen. , 1998, Immunology today.

[28]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[29]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[30]  H. Rammensee,et al.  Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.

[31]  A. Enk,et al.  Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions , 1997, European journal of immunology.

[32]  R. Figlin,et al.  Renal cell carcinoma: recent progress and future directions. , 1997, Cancer research.

[33]  H. Klocker,et al.  Prostaglandin E2 and Tumor Necrosis Factor ␣ Cooperate to Activate Human Dendritic Cells: Synergistic Activation of Interleukin 12 Production , 1997 .

[34]  Antonio Lanzavecchia,et al.  Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells , 1997, Nature.

[35]  F. Marshall,et al.  Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.

[36]  G. Murphy,et al.  Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigen , 1996, The Prostate.

[37]  H. Klocker,et al.  Human renal‐cell carcinoma tissue contains dendritic cells , 1996, International journal of cancer.

[38]  H. Klocker,et al.  Tumor‐infiltrating T lymphocytes from renal‐cell carcinoma express B7‐1 (CD80): T‐Cell expansion by T‐T cell co‐stimulation , 1995, International journal of cancer.

[39]  C Danieli,et al.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.

[40]  E. Jaffee,et al.  Gene therapy: its potential applications in the treatment of renal-cell carcinoma. , 1995, Seminars in oncology.

[41]  R. Steinman,et al.  Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.

[42]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[43]  H. Claésson,et al.  Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. , 1989, Journal of immunology.

[44]  A. Belldegrun,et al.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. , 1988, Cancer research.

[45]  I TOEROE,et al.  [ON THE LYMPH NODES]. , 1964, Verhandlungen der Anatomischen Gesellschaft.

[46]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.